Buy Becton Dickinson

Logo for stock BDX (Becton Dickinson)

Amount

£
GBP

Latest price

$176.37
(£1.00 = $1.328)

Number of shares (est.)

0

Start investing today

Open an investment account in Emma and enjoy commission free stock trading. Capital at risk, other charges apply.

QR code linking to downloads for the Emma app.
Download on the App Store buttonGet it on Google Play button

Metrics

Market Cap

$50.549B

P/E ratio

34.16

EPS

$5.163

Beta

0.27

Dividend rate

$3.98

Dividend yield

2.26%

About

Becton, Dickinson and Company is a global medical technology company. The Company is engaged in the development, manufacture and sale of a broad range of medical supplies, devices, laboratory equipment and diagnostic products used by healthcare institutions, physicians, life science researchers, clinical laboratories, and more. Its BD Medical segment produces an array of medical technologies and devices that are used to help improve healthcare delivery in a range of settings. The BD Medical segment consists of various business units, including medication delivery solutions, medication management solutions, advanced monitoring, and pharmaceutical systems. Its BD Life Sciences segment provides products for the collection and transport of diagnostics specimens, and instruments and reagent systems to detect a range of infectious diseases, healthcare-associated infections and cancers. Its BD Interventional segment provides vascular, urology, oncology and surgical specialty products.

CEO

Mr. Thomas E. Polen

Employees

74,000

Sector

Health

Company HQ

FRANKLIN LAKES, United States of America

Website

News

Logo for news article #0 (BD Aims to Save Lives by Empowering Women with Choice and Access to Cervical Cancer Screening Self-Collected At Home)

BD Aims to Save Lives by Empowering Women with Choice and Access to Cervical Cancer Screening Self-Collected At Home

New FDA Submission Includes Self-Collection Swab and High-Tech Laboratory Robotics that Report More High-Risk HPV Strains Than Any Other Test FRANKLIN LAKES, N.J. , July 31, 2025 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced it has submitted an application to the U.S. Food and Drug Administration for a new, at-home human papillomavirus (HPV) test that enables patients to self-collect a sample in the comfort of their own home using a swab the size of a Q-tip that simplifies processing at the lab and reports more high-risk strains of HPV than any other test on the market today.

PRNewsWire

July 31, 2025

Logo for news article #1 (Earnings Preview: Becton Dickinson (BDX) Q3 Earnings Expected to Decline)

Earnings Preview: Becton Dickinson (BDX) Q3 Earnings Expected to Decline

Becton Dickinson (BDX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Investment Research

July 31, 2025

Logo for news article #2 (BD Receives FDA 510(k) Clearance for Rapid Point-of-Care COVID-19 Test)

BD Receives FDA 510(k) Clearance for Rapid Point-of-Care COVID-19 Test

New CLIA-Waived Test Delivers Digital Results to Support Timely Clinical Decision-Making FRANKLIN LAKES, N.J. , July 30, 2025 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced it has received U.S. Food and Drug Administration (FDA) 510(k) clearance for the BD Veritor™ System for SARS-CoV-2, a digital test designed to detect COVID-19 antigens in symptomatic individuals in about 15 minutes at doctors' offices, urgent care centers, retail clinics and other convenient points of care.

PRNewsWire

July 30, 2025

Emma logo
Facebook logoTiktok logoTwitter / X logoInstagram logo

© 2025 Emma Technologies Ltd. All Rights Reserved.

Emma is registered and incorporated in England and Wales.

Emma Technologies Ltd is an appointed representative of RiskSave Technologies Ltd, which is authorised and regulated by the Financial Conduct Authority (FRN 775330).

Payment services (Non MIFID or Deposit related products) for Emma Technologies Ltd are provided by The Currency Cloud Limited. Registered in England No. 06323311. Registered Office: Stewardship Building 1st Floor, 12 Steward Street London E1 6FQ. The Currency Cloud Limited is authorised by the Financial Conduct Authority under the Electronic Money Regulations 2011 for the issuing of electronic money (FRN: 900199). For more detail on how your money is protected please see here. You can also find Currency Cloud's Terms of Use here.

Emma Technologies is an Introducer Appointed Representative of Quint Group Limited and not a lender. Quint Group Limited is authorised and regulated by the Financial Conduct Authority (Firm Reference Number 669450). Monevo Limited is an Appointed Representative of TransUnion International UK Limited. TransUnion is authorised and regulated by the Financial Conduct Authority (Firm Reference Number 737740). Emma Technologies introduces customers first to Quint Group Limited, as a licensed credit broker, who then refers on to Monevo Limited.

Emma is registered with the Financial Conduct Authority under the Payment Services Regulations 2017 for the provision of payment services.

Financial Conduct Authority Reg Nr: 794952.
Company Registration Number: 10578464.
Data Protection Registration Number: ZA241546.

All testimonials, reviews, opinions or case studies presented on our website may not be indicative of all customers. Results may vary and customers agree to proceed at their own risk.